Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.39 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | GSK3B | P49841 | 5/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9375538 | 0.73 | MEN1 (0.48) | MEN1KMT2ACRBNCYP11B1CYP11B2 | |
| SCHEMBL14463930 | 0.73 | CHRM1 (0.40) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13865329 | 0.72 | BRD4 (0.50) | MEN1KMT2ACRBNBRD4CREBBP | |
| SCHEMBL9371717 | 0.70 | KDM4E (0.33) | HPGDGAA | |
| SCHEMBL29696505 | 0.69 | CCNB2 (0.47) | MEN1KMT2ACCNB2CDK1CCNB1 | |
| SCHEMBL5068051 | 0.69 | MEN1 (0.62) | MEN1KMT2ACRBNCCNB2CDK1 | |
| SCHEMBL5025454 | 0.68 | NPC1 (0.41) | MEN1KMT2ACRBNCCNB2CDK1 | |
| SCHEMBL9263054 | 0.68 | CCNB2 (0.38) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL7278846 | 0.68 | MEN1 (0.53) | MEN1KMT2ACRBNCYP11B1CYP11B2 | |
| SCHEMBL7142836 | 0.66 | MEN1 (0.47) | MEN1KMT2ACRBNCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051316-B | Pentacyclic compounds | 卫材R&D管理有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3680243-B1 | PENTACYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3680243-B1 | PENTACYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3680243-A1 | PENTACYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3680243-A1 | PENTACYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-10239889-B1 | Pentacyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| US-10239889-B1 | Pentacyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| WO-2019049869-A1 | PENTACYCLIC COMPOUND | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2019-03-14 | — | — | WO | disclosed |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-4359420-A | HYPOTENSIVE AGENT, MUSCLE RELAXANTS | HOFFMANN-LA ROCHE INC. (US) | 1982-11-16 | — | — | US | disclosed |
| US-4346034-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346032-A | ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346030-A | ANTIDOTES FOR OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346035-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346036-A | ALKYLATION; AMIDATION; TRANQUILIZER ANTAGONIST | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346031-A | Process for preparing imidazodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346033-A | Thienodiazepinone and benzodiazepinone intermediates | HOFFMANN-LA ROCHE INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4316839-A | Imidazodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0027214-A1 | Imidazodiazepine derivatives, process and intermediates for their preparation, medicaments containing them and their therapeutic application | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239889-B1 | Pentacyclic compound | CYP2B6, CYP11B2, CYP3A5 | MEN1 234/4885KMT2A 4721/4885CRBN 3811/4885 |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | CYP2B6, CYP3A5, CYP4A11 | MEN1 322/4885KMT2A 4674/4885CRBN 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.